|MDACC Study No:||2012-0434 (clinicaltrials.gov NCT No: NCT01756677)|
|Title:||A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia|
|Principal Investigator:||Farhad Ravandi-Kashani|
|Treatment Agent:||Cytarabine; Lintuzumab-Ac225|
|Study Description:||The goal of the Phase 1 part of this study is to find the highest tolerable |
dose of Lintuzumab-Ac225 that can be given with cytarabine to patients with AML.
The goal of the Phase 2 part of this study is to learn if Lintuzumab-Ac225 and
cytarabine can control AML. The safety of this drug combination will also be
Lintuzumab-Ac225 is designed to deliver radiation therapy directly inside
leukemia cells without giving any radiation to the surrounding normal cells
Cytarabine is designed to insert itself into DNA (genetic material) of cancer
cells and stop the DNA from repairing itself.